THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its ...
Poster #53: Listening to Patients with Diabetic Peripheral Neuropathic Pain: Insights from a Patient Survey to Inform Advanced Clinical Development of Pilavapadin Date: September 4, 2025 Time: 4:00 ...
Lexicon Pharmaceuticals (NASDAQ: LXRX) presented its first quarter 2025 earnings on May 13, highlighting financial restructuring efforts and strategic partnerships amid ongoing revenue challenges. The ...
Presenters: Belinda Hardin, PharmD, BCPS, Senior Director, Medical Communications, and Suma Gopinathan, M.S, Ph.D., Senior Vice President, Discovery, Lexicon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results